The divergence between the TTM P/E of 29.28 and the forward multiple suggests the market anticipates significant earnings expansion as milestone payments normalize and royalty streams from established blockbusters scale. This valuation profile implies that investors are increasingly viewing the ENHANZE platform as a defensive, cash-generative asset, warranting a closer look at whether the current multiple adequately compensates for the long-term patent expiration risks.

The disparity between ROE and ROIC suggests that the company's capital structure, specifically its elevated debt levels, significantly amplifies equity returns during profitable periods. Analysts should monitor whether the integration of Antares Pharma assets will sustainably improve these returns or if the increased operational complexity will continue to weigh on the efficiency of invested capital.

The high DSO and DIO figures suggest that the company's revenue recognition timing is heavily dependent on partner reporting cycles and milestone achievement, rather than standard commercial sales velocity. This creates a persistent working capital drag that necessitates a larger liquidity buffer than would be required for a business with more predictable, short-cycle cash inflows.

While the interest coverage ratio remains healthy at 33.50, the absolute level of debt relative to equity suggests that the company's balance sheet is less resilient to potential shocks in royalty revenue. Investors should consider whether the current leverage profile limits the company's ability to pursue future strategic acquisitions or if it necessitates a shift toward debt reduction in the coming fiscal periods.